GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Owner Earnings per Share (TTM)

Concert Pharmaceuticals (Concert Pharmaceuticals) Owner Earnings per Share (TTM) : -2.47 (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Concert Pharmaceuticals's Owner Earnings per Share (TTM) ended in Sep. 2022 was $-2.47. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Concert Pharmaceuticals's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 11 years, the highest Price-to-Owner-Earnings ratio of Concert Pharmaceuticals was 7.13. The lowest was 0.00. And the median was 4.49.


CNCE's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.19
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Concert Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $-0.58. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.21. It's PE Ratio ratio for today is At Loss.

Concert Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2022 was $-0.58. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-3.21. It's PE Ratio without NRI ratio for today is At Loss.


Concert Pharmaceuticals Owner Earnings per Share (TTM) Historical Data

The historical data trend for Concert Pharmaceuticals's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals Owner Earnings per Share (TTM) Chart

Concert Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.86 -2.22 -2.58 -2.60 -2.01

Concert Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.75 -2.01 -2.32 -2.85 -2.47

Competitive Comparison of Concert Pharmaceuticals's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Concert Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concert Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's Price-to-Owner-Earnings falls into.



Concert Pharmaceuticals Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Concert Pharmaceuticals's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -126.31
Depreciation, Depletion and Amortization 1.27
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.85
Change In Working Capital 3.05
Shares Outstanding (Diluted Average) 49.73

1. Start with "Net Income" from income statement. Concert Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Sep. 2022 was $-126.31 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Concert Pharmaceuticals's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2022 was $1.27 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Concert Pharmaceuticals's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.85 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Concert Pharmaceuticals's 5-Year Average Maintenance Capital Expenditure = $0.85 Mil

5. "Change In Working Capital" is from cashflow statement. Concert Pharmaceuticals's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 was $3.05 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Concert Pharmaceuticals's Shares Outstanding (Diluted Average) for the months ended in Sep. 2022 was 49.731 Mil.

Concert Pharmaceuticals's Onwer Earnings Per Share for Sep. 2022 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -126.309 +1.267+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.84523254238898+3.049)/49.731
=-2.47

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=8.37/-2.47
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Concert Pharmaceuticals Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Executives
James V Cassella officer: Chief Development Officer 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker officer: CFO, PFO 175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart officer: Chief Operating Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie officer: Chief Legal Officer CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung director, officer: Chief Executive Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt director
Thomas G Auchincloss director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich director 1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland director C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Concert Pharmaceuticals (Concert Pharmaceuticals) Headlines

From GuruFocus

Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

By Business Wire Business Wire 08-04-2022

Concert Pharmaceuticals Announces Pricing of Public Offering

By Business Wire Business Wire 06-02-2022

This Insider Just Sold Shares of Concert Pharmaceuticals Inc

By GuruFocus Research GuruFocus Editor 01-10-2023